COMPARISON OF CLINICAL OUTCOMES OF SITAGLIPTIN AND GLICLAZIDE IN THE MANAGEMENT OF UNCOMPLICATED TYPE 2 DIABETES MELLITUS

This study evaluated and compared the efficacy and safety of sitagliptin and gliclazide in patients with uncomplicated type 2 diabetes mellitus. A total of 291 patients were assigned to two treatment groups receiving either sitagliptin or gliclazide. Glycemic parameters, including fasting blood glucose, postprandial blood glucose, and glycated hemoglobin levels, were assessed over a period of six months. Adverse effects, particularly episodes of hypoglycemia, were also monitored to evaluate safety. Both treatment groups showed significant improvement in glycemic control over time. However, gliclazide demonstrated a more consistent and greater reduction in fasting and postprandial blood glucose levels. A statistically significant reduction in glycated hemoglobin was observed in the gliclazide group, whereas the reduction in the sitagliptin group did not reach statistical significance. In terms of safety, gliclazide was associated with a higher incidence of hypoglycemic episodes. Sitagliptin, although producing relatively modest improvements in glycemic parameters, exhibited a more favorable safety profile with fewer hypoglycemic events. In conclusion, gliclazide provides superior glycemic control in patients with uncomplicated type 2 diabetes mellitus, while sitagliptin may be preferred in patients where avoidance of hypoglycemia is a major concern. These findings highlight the importance of individualized therapy based on efficacy and safety considerations.